Why the study?
Major depressive disorder is linked to higher cardio-metabolic comorbidity, but heterogeneity is large and immune-inflammatory and metabolic dysregulation affects only a subset of cases.
Are specific depression dimensional profilers associated with immuno-metabolic dysregulation over time?
Are specific depression dimensional profilers associated with immuno-metabolic dysregulation over time?
Patients with atypical energy-related depression symptoms may represent a high-risk group for cardiometabolic disease who could benefit from targeted prevention.
Answers are grounded in this paper and cite their sources.
Atypical energy-related symptoms associate with worse immuno-metabolic profiles in MDD; leaves open prospective prediction of cardio-metabolic risk.
BACKGROUND: Major depressive disorder (MDD) is linked to higher cardio-metabolic comorbidity that may in part be due to the low-grade inflammation and poorer metabolic health observed in MDD. Heterogeneity of MDD is however large, and immune-inflammatory and metabolic dysregulation is present in only part of the MDD cases. We examined the associations of four depression dimensional profilers (atypical energy-related symptom dimension, melancholic symptom dimension, childhood trauma severity, and anxious distress symptom dimension) with immuno-metabolic outcomes, both cross-sectionally and longitudinally. METHODS: Three waves covering a 6-year follow-up (>7000 observations) of the Netherlands Study of Depression and Anxiety (NESDA) were used. Depression profilers were based on the Inventory of Depressive Symptomatology, the Beck Anxiety Inventory, and the Childhood Trauma index. An inflammatory index (based on IL-6 and CRP), a metabolic syndrome index (based on the five metabolic syndrome components), and a combination of these two indices were constructed. Mixed models were used for cross-sectional and longitudinal models, controlling for covariates. RESULTS: Of the four depression profilers, only the atypical, energy-related symptom dimension showed robust associations with higher scores on the inflammatory, metabolic syndrome and combined inflammatory-metabolic indexes cross-sectionally, as well as at follow-up. The melancholic symptom dimension was associated with lower scores on the metabolic syndrome index both cross-sectionally and longitudinally. CONCLUSION: The atypical energy-related symptom dimension was linked to poorer immune-inflammatory and metabolic health, while the melancholic symptom dimension was linked to relatively better metabolic health. Persons with high atypical energy-related symptom burden, representing an immuno-metabolic depression, may be the most important group to target in prevention programs for cardiometabolic disease, and may benefit most from treatments targeting immuno-metabolic pathways.
No takes yet. Share an insight, caveat, or question.
Lamers et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: